EUCRISA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Eucrisa, and what generic alternatives are available?
Eucrisa is a drug marketed by Anacor Pharms Inc and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.
This drug has one hundred and forty-eight patent family members in twenty-eight countries.
The generic ingredient in EUCRISA is crisaborole. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the crisaborole profile page.
DrugPatentWatch® Generic Entry Outlook for Eucrisa
Eucrisa was eligible for patent challenges on December 14, 2020.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be December 29, 2029. This may change due to patent challenges or generic licensing.
There have been five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for EUCRISA?
- What are the global sales for EUCRISA?
- What is Average Wholesale Price for EUCRISA?
Summary for EUCRISA
| International Patents: | 148 |
| US Patents: | 4 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 95 |
| Clinical Trials: | 16 |
| Patent Applications: | 142 |
| Drug Prices: | Drug price information for EUCRISA |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for EUCRISA |
| What excipients (inactive ingredients) are in EUCRISA? | EUCRISA excipients list |
| DailyMed Link: | EUCRISA at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for EUCRISA
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for EUCRISA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Colorado, Denver | Phase 2 |
| Boston University | Phase 4 |
| Applied Biology, Inc. | Phase 3 |
Pharmacology for EUCRISA
| Drug Class | Phosphodiesterase 4 Inhibitor |
| Mechanism of Action | Phosphodiesterase 4 Inhibitors |
Paragraph IV (Patent) Challenges for EUCRISA
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| EUCRISA | Topical Ointment | crisaborole | 2% | 207695 | 5 | 2021-06-14 |
US Patents and Regulatory Information for EUCRISA
EUCRISA is protected by four US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of EUCRISA is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting EUCRISA
Boron-containing small molecules
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Boron-containing small molecules as anti-inflammatory agents
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Boron-containing small molecules as anti-inflammatory agents
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Boron-containing small molecules as anti-inflammatory agents
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
FDA Regulatory Exclusivity protecting EUCRISA
ADDITION OF A ONCE DAILY DOSING REGIMEN
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anacor Pharms Inc | EUCRISA | crisaborole | OINTMENT;TOPICAL | 207695-001 | Dec 14, 2016 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Anacor Pharms Inc | EUCRISA | crisaborole | OINTMENT;TOPICAL | 207695-001 | Dec 14, 2016 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Anacor Pharms Inc | EUCRISA | crisaborole | OINTMENT;TOPICAL | 207695-001 | Dec 14, 2016 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Anacor Pharms Inc | EUCRISA | crisaborole | OINTMENT;TOPICAL | 207695-001 | Dec 14, 2016 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Anacor Pharms Inc | EUCRISA | crisaborole | OINTMENT;TOPICAL | 207695-001 | Dec 14, 2016 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for EUCRISA
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Pfizer Europe MA EEIG | Staquis | crisaborole | EMEA/H/C/004863 Staquis is indicated for treatment of mild to moderate atopic dermatitis in adults and paediatric patients from 2 years of age with ≤ 40% body surface area (BSA) affected. |
Withdrawn | no | no | no | 2020-03-27 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for EUCRISA
When does loss-of-exclusivity occur for EUCRISA?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 06214247
Patent: Boron-containing small molecules
Estimated Expiration: ⤷ Sign Up
Patent: 06333527
Patent: Boron-containing small molecules
Estimated Expiration: ⤷ Sign Up
Patent: 10203096
Patent: Boron-containing small molecules
Estimated Expiration: ⤷ Sign Up
Patent: 11200994
Patent: Boron-containing small molecules
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 0608431
Patent: móleculas pequenas contendo boro
Estimated Expiration: ⤷ Sign Up
Patent: 0621279
Patent: moléculas pequenas contendo boro
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 97982
Patent: PETITES MOLECULES CONTENANT DU BORE (BORON-CONTAINING SMALL MOLECULES)
Estimated Expiration: ⤷ Sign Up
Patent: 35680
Patent: PETITES MOLECULES CONTENANT DU BORE (BORON-CONTAINING SMALL MOLECULES)
Estimated Expiration: ⤷ Sign Up
China
Patent: 1160124
Patent: Boron-containing small molecules
Estimated Expiration: ⤷ Sign Up
Patent: 1505603
Patent: Boron-containing small molecules
Estimated Expiration: ⤷ Sign Up
Patent: 1914109
Patent: Boron-containing small molecules
Estimated Expiration: ⤷ Sign Up
Patent: 2532180
Patent: Boron-containing small molecules
Estimated Expiration: ⤷ Sign Up
Patent: 5949230
Patent: 含硼的小分子 (BORON-CONTAINING SMALL MOLECULES)
Estimated Expiration: ⤷ Sign Up
Patent: 6008571
Patent: 含硼的小分子 (Boron-containing small molecules)
Estimated Expiration: ⤷ Sign Up
Patent: 6008583
Patent: 含硼的小分子 (BORON-CONTAINING SMALL MOLECULES)
Estimated Expiration: ⤷ Sign Up
Cyprus
Patent: 16454
Estimated Expiration: ⤷ Sign Up
Patent: 20695
Estimated Expiration: ⤷ Sign Up
Patent: 24503
Estimated Expiration: ⤷ Sign Up
Patent: 20027
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 43304
Estimated Expiration: ⤷ Sign Up
Patent: 87796
Estimated Expiration: ⤷ Sign Up
Patent: 24932
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 53251
Patent: BORONOPHTHALIDES SUBSTITUES PAR HALOGENE POUR LE TRAITEMENT D'INFECTIONS (HALOGEN-SUBSTITUTED BORONOPHTHALIDES FOR THE TREATMENT OF INFECTIONS)
Estimated Expiration: ⤷ Sign Up
Patent: 76536
Patent: PETITES MOLECULES CONTENANT DU BORE (BORON-CONTAINING SMALL MOLECULES)
Estimated Expiration: ⤷ Sign Up
Patent: 43304
Patent: Composés boronophthalide biocides (Biocidal boronophthalide compounds)
Estimated Expiration: ⤷ Sign Up
Patent: 87796
Patent: BORONOPHTHALIDES SUBSTITUES PAR HALOGENE POUR LE TRAITEMENT D'INFECTIONS (HALOGEN-SUBSTITUTED BORONOPHTHALIDES FOR THE TREATMENT OF INFECTIONS)
Estimated Expiration: ⤷ Sign Up
Patent: 24932
Patent: BORONOPHTHALIDES À USAGE THÉRAPEUTIQUE (BORONOPHTHALIDES FOR THERAPEUTIC USE)
Estimated Expiration: ⤷ Sign Up
France
Patent: C1024
Estimated Expiration: ⤷ Sign Up
Hong Kong
Patent: 09735
Patent: HALOGEN-SUBSTITUTED BORONOPHTHALIDES FOR THE TREATMENT OF INFECTIONS
Estimated Expiration: ⤷ Sign Up
Patent: 60139
Patent: 殺生物二羥硼基 -苯並 呋喃酮化合物 (BIOCIDAL BORONOPHTHALIDE COMPOUNDS 2-[C])
Estimated Expiration: ⤷ Sign Up
Patent: 21956
Patent: 用於治療感染的鹵代類苯酞化硼 (HALOGEN-SUBSTITUTED BORONOPHTHALIDES FOR THE TREATMENT OF INFECTIONS)
Estimated Expiration: ⤷ Sign Up
Patent: 28917
Patent: 含硼的小分子 (BORON-CONTAINING SMALL MOLECULES)
Estimated Expiration: ⤷ Sign Up
Hungary
Patent: 26021
Estimated Expiration: ⤷ Sign Up
Patent: 40060
Estimated Expiration: ⤷ Sign Up
Patent: 54365
Estimated Expiration: ⤷ Sign Up
Patent: 000019
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 5080
Patent: BORON-CONTAINING SMALL MOLECULES, PHARMACEUTICAL FORMULATIONS COMPRISING THEM AND USE THEREOF IN THE PREPARATION OF MEDICAMENTS FOR TREATING INFECTIONS
Estimated Expiration: ⤷ Sign Up
Patent: 2402
Patent: מולקולות קטנות המכילות בורון (Boron-containing small molecules)
Estimated Expiration: ⤷ Sign Up
Patent: 7156
Patent: מולקולות קטנות המכילות בור (Boron-containing small molecules)
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 38912
Estimated Expiration: ⤷ Sign Up
Patent: 46876
Estimated Expiration: ⤷ Sign Up
Patent: 09140
Estimated Expiration: ⤷ Sign Up
Patent: 08535781
Estimated Expiration: ⤷ Sign Up
Patent: 09526751
Estimated Expiration: ⤷ Sign Up
Patent: 10248265
Patent: BORON-CONTAINING SMALL MOLECULE
Estimated Expiration: ⤷ Sign Up
Patent: 13018778
Patent: BORON-CONTAINING SMALL MOLECULE
Estimated Expiration: ⤷ Sign Up
Patent: 14132031
Patent: BORON-CONTAINING SMALL MOLECULES
Estimated Expiration: ⤷ Sign Up
Patent: 15117243
Patent: ホウ素含有小分子 (BORON-CONTAINING SMALL MOLECULES)
Estimated Expiration: ⤷ Sign Up
Patent: 16020374
Patent: ホウ素含有小分子 (BORON-CONTAINING SMALL MOLECULE)
Estimated Expiration: ⤷ Sign Up
Patent: 16199561
Patent: ホウ素含有小分子 (BORON-CONTAINING SMALL MOLECULES)
Estimated Expiration: ⤷ Sign Up
Patent: 17105826
Patent: ホウ素含有小分子 (BORON-CONTAINING SMALL MOLECULE)
Estimated Expiration: ⤷ Sign Up
Lithuania
Patent: 343304
Estimated Expiration: ⤷ Sign Up
Patent: 2020524
Estimated Expiration: ⤷ Sign Up
Luxembourg
Patent: 0157
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 5993
Patent: MOLECULAS PEQUEÑAS QUE CONTIENEN BORO. (BORON-CONTAINING SMALL MOLECULES.)
Estimated Expiration: ⤷ Sign Up
Patent: 9262
Patent: MOLECULAS PEQUEÑAS QUE CONTIENEN BORO. (BORON-CONTAINING SMALL MOLECULES.)
Estimated Expiration: ⤷ Sign Up
Netherlands
Patent: 1049
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 0448
Patent: Boron-containing small molecules
Estimated Expiration: ⤷ Sign Up
Patent: 8297
Patent: Boron-containing small molecules
Estimated Expiration: ⤷ Sign Up
Patent: 8441
Patent: BORON-CONTAINING SMALL MOLECULES
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 53251
Estimated Expiration: ⤷ Sign Up
Patent: 43304
Estimated Expiration: ⤷ Sign Up
Patent: 87796
Estimated Expiration: ⤷ Sign Up
Patent: 24932
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 53251
Estimated Expiration: ⤷ Sign Up
Patent: 43304
Estimated Expiration: ⤷ Sign Up
Patent: 87796
Estimated Expiration: ⤷ Sign Up
Patent: 24932
Estimated Expiration: ⤷ Sign Up
Russian Federation
Patent: 14906
Patent: БОРСОДЕРЖАЩИЕ МАЛЫЕ МОЛЕКУЛЫ (BORON-CONTAINING SMALL MOLLECULES)
Estimated Expiration: ⤷ Sign Up
Patent: 06947
Patent: БОРСОДЕРЖАЩИЕ МАЛЫЕ МОЛЕКУЛЫ (BORON-CONTAINING SMALL MOLECULES)
Estimated Expiration: ⤷ Sign Up
Patent: 07134429
Patent: БОРСОДЕРЖАЩИЕ МАЛЫЕ МОЛЕКУЛЫ
Estimated Expiration: ⤷ Sign Up
Patent: 08131324
Patent: БОРСОДЕРЖАЩИЕ МАЛЫЕ МОЛЕКУЛЫ
Estimated Expiration: ⤷ Sign Up
Patent: 10133524
Patent: БОРСОДЕРЖАЩИЕ МАЛЫЕ МОЛЕКУЛЫ
Estimated Expiration: ⤷ Sign Up
Patent: 16145916
Patent: БОРСОДЕРЖАЩИЕ МАЛЫЕ МОЛЕКУЛЫ
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 43304
Estimated Expiration: ⤷ Sign Up
Patent: 87796
Estimated Expiration: ⤷ Sign Up
Patent: 24932
Estimated Expiration: ⤷ Sign Up
South Africa
Patent: 0707408
Patent: Boron-containing small molecules
Estimated Expiration: ⤷ Sign Up
Patent: 0905950
Patent: BORON-CONTAINING SMALL MOLECULES
Estimated Expiration: ⤷ Sign Up
Patent: 1005380
Patent: BORON-CONTAINING SMALL MOLECULES
Estimated Expiration: ⤷ Sign Up
Patent: 1506944
Patent: BORON-CONTAINING SMALL MOLECULES
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 1337045
Estimated Expiration: ⤷ Sign Up
Patent: 1337068
Estimated Expiration: ⤷ Sign Up
Patent: 1426220
Estimated Expiration: ⤷ Sign Up
Patent: 1456815
Estimated Expiration: ⤷ Sign Up
Patent: 070112390
Patent: BORON-CONTAINING SMALL MOLECULES
Estimated Expiration: ⤷ Sign Up
Patent: 080110984
Patent: BORON-CONTAINING SMALL MOLECULES
Estimated Expiration: ⤷ Sign Up
Patent: 100105869
Patent: BORON-CONTAINING SMALL MOLECULES
Estimated Expiration: ⤷ Sign Up
Patent: 130095330
Patent: BORON-CONTAINING SMALL MOLECULES
Estimated Expiration: ⤷ Sign Up
Patent: 130100019
Patent: BORON-CONTAINING SMALL MOLECULES
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 14095
Estimated Expiration: ⤷ Sign Up
Patent: 40966
Estimated Expiration: ⤷ Sign Up
Patent: 86981
Estimated Expiration: ⤷ Sign Up
Patent: 72962
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering EUCRISA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Mexico | 360301 | MOLECULAS PEQUEÑAS QUE CONTIENEN BORO COMO AGENTES ANTIINFLAMATORIOS. (BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS.) | ⤷ Sign Up |
| China | 105949230 | 含硼的小分子 (BORON-CONTAINING SMALL MOLECULES) | ⤷ Sign Up |
| Japan | 2010248265 | BORON-CONTAINING SMALL MOLECULE | ⤷ Sign Up |
| South Korea | 20170012570 | 항염증제로서 보론함유 소분자 (BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS) | ⤷ Sign Up |
| South Korea | 101819869 | ⤷ Sign Up | |
| Japan | 2008535781 | ⤷ Sign Up | |
| European Patent Office | 1976536 | PETITES MOLECULES CONTENANT DU BORE (BORON-CONTAINING SMALL MOLECULES) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for EUCRISA
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2343304 | 122020000038 | Germany | ⤷ Sign Up | PRODUCT NAME: CRISABOROL, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES DAVON; REGISTRATION NO/DATE: EU/1/19/1421 20200327 |
| 2343304 | C202030031 | Spain | ⤷ Sign Up | PRODUCT NAME: CRISABOROL, OPCIONALMENTE EN FORMA DE UNA SAL FARMACEUTICAMENTE ACEPTABLE; NATIONAL AUTHORISATION NUMBER: EU/1/19/1421; DATE OF AUTHORISATION: 20200327; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/19/1421; DATE OF FIRST AUTHORISATION IN EEA: 20200327 |
| 2343304 | 2090017-1 | Sweden | ⤷ Sign Up | PRODUCT NAME: CRISABOROLE, OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALT; REG. NO/DATE: EU/1/19/1421 20200401 |
| 2343304 | 2020/024 | Ireland | ⤷ Sign Up | PRODUCT NAME: CRISABOROLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTRATION NO/DATE: EU/1/19/1421/001 EU/1/19/1421/004 20200327 |
| 2343304 | SPC/GB20/025 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: CRISABOROLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/19/1421 20200401; UK PLGB 00057-1691 20200401 |
| 2343304 | 2020C/531 | Belgium | ⤷ Sign Up | PRODUCT NAME: CRISABOROLE, OPTIONEEL IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT HIERVAN; AUTHORISATION NUMBER AND DATE: EU/1/19/1421 20200401 |
| 2343304 | CA 2020 00022 | Denmark | ⤷ Sign Up | PRODUCT NAME: CRISABOROLE, EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/19/1421 20200401 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
